For most expectant mothers, the third trimester is a time of nesting and final preparations. However, for some, it is marked by a relentless, exhausting itch that signals a deeper underlying condition: Intrahepatic Cholestasis of Pregnancy (ICP). Formerly known as obstetric cholestasis, ICP is a multifactorial liver disorder unique to pregnancy. It demands careful, evidence-based management to navigate maternal discomfort and safeguard the fetus.
Drawing from the Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 43, this post reviews the clinical journey of ICP—from a classic presentation through diagnosis, management, delivery, and postpartum follow-up.
The Clinical Scenario: “It’s Driving Me Crazy, Especially at Night”
Consider Sarah, a 31-year-old woman at 33 weeks of gestation in her first singleton pregnancy. She presents to the antenatal clinic complaining of severe, unyielding pruritus that began a week ago. The itching started on the palms of her hands and the soles of her feet but has since become generalized. She reports no rashes, but her skin shows minor excoriations (scratch marks). The itch is significantly worse at night, causing profound sleep deprivation and heightened anxiety.
Step 1: Making the Diagnosis
The primary clinical marker of ICP is pruritus in the absence of a primary skin condition. In Sarah’s case, a physical examination confirms her skin is otherwise normal. Her obstetric team immediately orders a non-fasting blood test to measure her total serum bile acid concentrations and liver function tests (LFTs).
According to the latest RCOG guidelines:
- The Diagnostic Threshold: A diagnosis of ICP is confirmed when unexplained itching of normal skin is paired with a raised peak total bile acid concentration of 19 µmol/L or more.
- Classification of Severity: ICP is stratified by the peak bile acid concentration recorded during the pregnancy:
- Mild ICP: 19–39 µmol/L
- Moderate ICP: 40–99 µmol/L
- Severe ICP: ≥100 µmol/L
Sarah’s lab results reveal an alanine transaminase (ALT) level of 120 U/L and a total bile acid concentration of 48 µmol/L. She is diagnosed with Moderate ICP.
Clinical Note: Routine underlying viral, autoimmune, or ultrasound screening is no longer recommended for uncomplicated presentations because the diagnostic yield is extremely low. They are reserved only for early-onset (1st/2nd trimester) or atypical cases.
Step 2: Risk Assessment and Antenatal Management
The primary driving force behind the close monitoring of ICP is the historical association with an increased risk of stillbirth. However, recent large-scale meta-analyses have brought immense reassurance to clinical practice by establishing that the risk of stillbirth only increases significantly above the general population rate when maternal serum bile acid concentrations reach 100 µmol/L or more.
Because Sarah’s bile acids are 48 µmol/L, her risk of stillbirth remains low and comparable to the background population risk up until 38–39 weeks.
Maternal Monitoring and Co-morbidities
ICP fluctuates and can progress in biochemical severity. Sarah is scheduled for weekly LFTs and bile acid monitoring to watch her trajectory. Furthermore, women with ICP have a significantly higher incidence of developing pre-eclampsia (12.2% vs. 3.4%) and gestational diabetes. Sarah’s care plan includes strict blood pressure monitoring, urinalysis, and standard diabetic screenings.
The Reality of Medical Therapy
Sarah asks about medications to help her baby and stop the itch. It is critical to provide honest, evidence-based counseling here:
- Perinatal Outcomes: There are currently no pharmacological treatments proven to improve adverse perinatal outcomes or reduce the risk of stillbirth.
- Ursodeoxycholic Acid (UDCA): While widely prescribed in the past, large randomized trials show UDCA offers limited benefit for maternal pruritus and does not reduce adverse perinatal outcomes. The RCOG explicitly recommends against routinely offering UDCA for the sole purpose of reducing adverse perinatal events.
- Sarah is offered topical emollients and a discussion regarding the limited, short-term benefits of treatment options to help maximize her comfort and sleep.
Step 3: Determining Delivery Timing and Intrapartum Care
The optimal timing of birth is a balanced decision negotiated through shared, informed decision-making. In an isolated singleton pregnancy with no other co-morbidities, the timing of planned birth is strictly guided by peak bile acid thresholds:
- Mild ICP (19–39 µmol/L): Discuss ongoing antenatal care or planned birth by 40 weeks.
- Moderate ICP (40–99 µmol/L): Consider planned birth at 38–39 weeks’ gestation, as the stillbirth risk begins to rise slightly around this window.
- Severe ICP (≥100 µmol/L): Advise planned birth early, at 35–36 weeks’ gestation, due to a distinct rise in stillbirth risk (3.44%).
At 37 weeks, Sarah’s bile acids remain steady in the moderate tier at 52 µmol/L. In consultation with her obstetrician, an induction of labour is planned and successfully scheduled at 38 weeks’ gestation.
Fetal Monitoring in Labour
It is vital to note that routine antenatal fetal ultrasounds and cardiotocography (CTG) do not accurately predict or prevent sudden stillbirths in the clinic for ICP patients. However, during active labour, the presence of moderate-to-severe ICP increases the risk of meconium-stained liquor. While continuous electronic fetal monitoring (CEFM) is mandatory for severe ICP (≥100 µmol/L), for moderate cases like Sarah’s, it is discussed as a shared choice based on her clinical progression and preferences. Sarah opts for regular monitoring, experiences an uncomplicated labour, and delivers a healthy infant.
Step 4: Postpartum Follow-Up and Monitoring
Postpartum care is where a definitive diagnosis of ICP is truly sealed. Sarah is relieved to find her intense itching resolves completely within 48 hours of delivery—a classic feature of the disease.
However, her care is not complete at discharge:
- The 4-to-6-Week Check: Sarah is scheduled for a postnatal review at least 4 to 6 weeks after birth.
- Biochemical Confirmation: Repeat total bile acids and LFTs must be drawn at this follow-up to confirm they have returned completely to normal limits. If abnormalities or itching persist beyond 6 weeks, an alternate or underlying hepatobiliary issue (such as gallstone disease or non-alcoholic fatty liver) must be suspected, and a referral to a hepatologist is initiated.
- Future Planning: Sarah is counseled that she has a substantially increased risk of ICP recurring in subsequent pregnancies. A baseline LFT and bile acid test will be mandatory at her booking appointment for any future pregnancy. Reassuringly, the history of uncomplicated ICP does not restrict her future contraceptive options, allowing her to safely use oestrogen- or progestogen-based methods provided her liver markers fully normalize.
Conclusion
Intrahepatic Cholestasis of Pregnancy is an incredibly distressing condition for the mother, but modern clinical guidelines provide a clear, safe, and reassuring map for practitioners. By shifting the clinical focus toward precise, peak bile acid stratification, we can avoid unnecessary early interventions for mild-to-moderate cases while dynamically protecting those at higher risk.
External References & Further Reading:
- RCOG Green-top Guideline No. 43:Intrahepatic cholestasis of pregnancy (June 2022). Green-top Guideline No. 43.
- Ovadia et al. (2019):Association of maternal serum bile acid concentration with adverse outcomes in intrahepatic cholestasis of pregnancy: an individual participant data meta-analysis. Lancet. (The foundational study establishing the 100 µmol/L threshold).
- ICP Support: A specialized charity offering valuable patient-facing information and community resources for families navigating this diagnosis (icpsupport.org).
